Skip to main content

Share story

Infrastructure

Sensitive data classification in the Trust Center

The Trust Center now supports sensitive data classification as part of a preview release. This capability lets users set up the classification process and examine the results afterward. Access to the feature comes through the existing Trust Center interface. The Data Security tab appears in the Trust Center user interface for this purpose. Through this tab, sensitive data can be classified into semantic categories. Name and age serve as examples of these categories. The classification happens without any need to write SQL code. Completion of the classification process opens additional options in the Data Security tab. Users can locate the specific objects that contain sensitive data. The tab delivers insights on the sensitive data present. These insights cover the number of objects that could fall under regulatory requirements. They also reveal whether a masking policy currently protects the sensitive data. Rollout of the sensitive data classification support occurs on a gradual schedule. The feature should become available in every account by February 1, 2026.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Snowflake and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.